NYSE:HIMSHealthcare
Regulatory Scrutiny Puts Hims And Hers GLP 1 Growth Story To The Test
Hims & Hers Health (NYSE:HIMS) is facing heightened regulatory and legal scrutiny over its compounded semaglutide weight loss pill, launched as a lower cost alternative to Wegovy.
The FDA has issued public statements targeting unapproved compounded GLP-1 drugs and has specifically referenced Hims & Hers in this context.
The Department of Health and Human Services has referred Hims & Hers to the Department of Justice for a potential investigation into federal law compliance.
Novo Nordisk is...